



# apoquel® (oclacitinib tablet)



## Product Name:

Apoquel 3.6mg Chewable Tablets for Dogs  
Apoquel 5.4mg Chewable Tablets for Dogs  
Apoquel 16mg Chewable Tablets for Dogs

## Strength of Active Substance(s):

Each Apoquel 3.6mg Chewable Tablets for Dogs contain 3.6mg of oclacitinib (as oclacitinib maleate).

Each Apoquel 5.4mg Chewable Tablets for Dogs contain 5.4mg of oclacitinib (as oclacitinib maleate).

Each Apoquel 16mg Chewable Tablets for Dogs contain 16mg of oclacitinib (as oclacitinib maleate).

## Product Description:

Chewable tablets.

### Apoquel 3.6mg Chewable Tablets for Dogs:

Light to dark brown colored, elongated pentagon shaped, mottled tablets with score lines on both sides. Debossed with SS on one side.

### Apoquel 5.4mg Chewable Tablets for Dogs:

Light to dark brown colored, elongated pentagon shaped, mottled tablets with score lines on both sides. Debossed with MM on one side.

### Apoquel 16mg Chewable Tablets for Dogs:

Light to dark brown colored, elongated pentagon shaped, mottled tablets with score lines on both sides. Debossed with LL on one side.

## Pharmacodynamics:

Oclacitinib is a Janus kinase (JAK) inhibitor. It can inhibit the function of a variety of cytokines dependent on JAK enzyme activity. For oclacitinib, the target cytokines are those that are proinflammatory or have a role in allergic responses/ pruritis. However, oclacitinib may also exert effects on other cytokines (for example, those involved in host defence or haematopoiesis) with the potential for unwanted effects.

## Pharmacokinetics:

Following oral administration in dogs at a dose ranging from 0.55 to 0.9 mg oclacitinib/kg bodyweight, the observed mean  $c_{max}$  was 352 ng/ml (ranging from 207 to 860 ng/ml), which occurred at approximately 1.7 hours ( $t_{max}$ ) post dosing. The half-life ( $t_{1/2}$ ) is 4.8 hours in plasma.

Total body oclacitinib clearance from plasma was low – 316 ml/h/kg bodyweight (5.3 ml/min/kg bodyweight), and the apparent volume of distribution at steady-state was 942 ml/kg bodyweight.

Oclacitinib exhibits low protein binding with 66.3% to 69.7% bound in fortified canine plasma at nominal concentrations ranging from 10 to 1,000 ng/ml.

Oclacitinib is metabolised in the dog to multiple metabolites. One major oxidative metabolite was identified in plasma and urine.

Overall, the major clearance route is metabolism, with minor contributions from renal and biliary elimination. Inhibition of canine cytochrome P450s is minimal, with  $IC_{50}$ s 50-fold greater than the observed mean  $C_{max}$  (281 ng/ml or 0.833  $\mu$ M) following 0.6 mg/kg bw oral administration in the target animal safety study. Therefore, the risk of metabolic drug-drug interactions due to oclacitinib inhibition is very low.

## Indications:

Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

## Target Species:

Dogs

## Recommended Dose:

The dose of Apoquel Chewable tablet is 0.4 to 0.6mg oclacitinib/kg body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. The requirement for

long-term maintenance therapy should be based on an individual benefit-risk assessment.

The tablets can be administered with or without food. The dosing table below shows the number of tablets required. The tablets are breakable along the score line.

Bodyweight (kg) of dog	Strength and number of tablets to be administered:		
	Apoquel 3.6mg Tablets	Apoquel 5.4mg Tablets	Apoquel 16mg Tablets
3.0 – 4.4	0.5		
4.5 – 5.9		0.5	
6.0 – 8.9	1		
9.0 – 13.4		1	
13.5 – 19.9			0.5
20.0 – 26.9		2	
27.0 – 39.9			1
40.0 – 54.9			1.5
55.0 – 80.0			2

## Contraindications:

Do not use in cases of hypersensitivity to the active substance or to any of the excipients. Do not use in dogs less than 12 months of age or less than 3 kg bodyweight. Do not use in dogs with evidence of immune suppression, such as hyperadrenocorticism, or with evidence of progressive malignant neoplasia as the active substance has not been evaluated in these cases.

## Warnings & Precautions:

### Warnings

None.

### Special Precautions for Use

#### Special precautions for use in animals:

Oclacitinib modulates the immune system and may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs receiving Apoquel tablets should therefore be monitored for the development of infections and neoplasia.

When treating pruritus associated with allergic dermatitis with oclacitinib, investigate and treat any underlying causes (e.g. flea allergic dermatitis, contact dermatitis, food hypersensitivity). Furthermore, in cases of allergic dermatitis and atopic dermatitis, it is recommended to investigate and treat complicating factors, such as bacterial, fungal or parasitic infections/infestations (e.g. flea and mange).

Given the potential for effects on certain clinicopathological parameters, periodic monitoring with complete blood counts and serum biochemistry is recommended when dogs are on long-term treatment.

The tablets are flavoured. In order to avoid accidental ingestion, store tablets in a safe place out of reach of animals.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands after administration.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Ingestion of this product may be harmful for children. To avoid accidental ingestion, administer the tablet(s) to the dog immediately after removal from the blister packaging.

For Animal Use Only.

Controlled Medicine / Ubat Terkawal.

Keep out of reach of children / Jauhi dari kanak-kanak.

## Interactions with Other Medicaments:

No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and antiinflammatories.

The impact of oclacitinib administration on vaccination with modified live vaccines,

canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naive puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight (bw) twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear.

## Pregnancy and Lactation:

The safety of the veterinary medicinal product has not been established during pregnancy and lactation, or in breeding male dogs, therefore its use is not recommended during pregnancy, lactation or in dogs intended for breeding.

## Side Effects:

Dogs:

<b>Very common</b> (>1 animal / 10 animals treated):	pyoderma, skin lump, papilloma
<b>Common</b> (1 to 10 animals / 100 animals treated):	lethargy, lipoma, polydipsia, increased appetite, nausea, vomiting, diarrhoea, anorexia, histiocytoma, fungal skin infection, pododermatitis, otitis, lymphadenopathy, cystitis, aggression
<b>Very rare</b> (<1 animal / 10,000 animals treated, including isolated reports):	anaemia, lymphoma, convulsion

Treatment-related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant. Regarding susceptibility to infection and neoplastic conditions, see section “Special precautions for use”. Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the product registration holder or the national competent authority via the national reporting system.

## Overdose:

Oclacitinib tablets were administered to healthy, one year old Beagle dogs twice daily for 6 weeks, followed by once per day for 20 weeks, at 0.6 mg/kg bw, 1.8 mg/kg bw and 3.0 mg/kg bw for a total of 26 weeks.

Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the feet.

Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more feet during the study, with the number and frequency of observations increasing with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increasing dose, and was frequently associated with interdigital furunculosis.

# apoquel®

(oclacitinib tablet)



Papilloma was considered treatment related, but not dose related.

There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically.

**Storage Condition:** Store below 30°C. Store in the original package in order to protect from moisture.

**Shelf Life (as packaged for sale):**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

**Shelf-life after first opening the container:**

Proposed Shelf Life of remaining ½ tablet in blister:

Store in the original package in order to protect from moisture. Remaining tablet parts should be stored in the blister and be given at the next administration.

Proposed Shelf Life of remaining tablets in bottle:

The product is suitable for use for maximum 60 days after broaching of induction seals and kept in closed condition in the original HDPE pack. Divided tablets need to be retained within the original package.

**Pack Size:**

Bottle of 100's count.

ALU / ACLAR blisters (each strip containing 10 chewable tablets) packed into an outer cardboard box. Pack sizes of 20, 50 or 100 tablets.

Not all pack sizes may be marketed.

**Disposal:** The material should be disposed of in accordance with local requirements.

**Manufactured by:**

Zoetis Inc  
2605 East Kilgore Road, Kalamazoo,  
Michigan 49001, United States

**zoetis**

**Product Registration Holder:**

Zoetis Malaysia Sdn Bhd  
Lot 3.1, Level 3, Tower 7, Avenue 3,  
Bangsar South, No 8 Jalan Kerinchi,  
59200 Kuala Lumpur, Malaysia

**Date of Revision:** 13 Feb 2025

NO COPY AREA

FPO  
12015